Equillium Announces $35 Million Financing with RA Capital Management

Rhea-AI Summary

Equillium (Nasdaq: EQ) entered a definitive securities purchase agreement with RA Capital Management to raise approximately $35 million gross through a PIPE announced March 13, 2026. The company will issue roughly 18.9 million shares (including pre-funded warrants) at about $1.854 per share.

Net proceeds are intended to advance clinical development of EQ504, support working capital and general corporate purposes, and are expected to extend the company’s cash runway into 2029. RA Capital received customary Form S-3 resale registration rights.

Positive

• $35 million gross PIPE financing
• Issuance of ~18.9 million shares and pre-funded warrants
• Proceeds expected to fund operations into 2029
• Strategic backing from RA Capital enhances investor confidence

Negative

• Issuance of ~18.9 million shares causes shareholder dilution
• Pre-funded warrants increase potential share supply
• RA Capital’s Form S-3 resale rights could increase near-term selling pressure

News Market Reaction – EQ

+19.32% 11.3x vol

20 alerts

+19.32% News Effect

+19.5% Peak in 7 hr 29 min

+$26M Valuation Impact

$160M Market Cap

11.3x Rel. Volume

On the day this news was published, EQ gained 19.32%, reflecting a significant positive market reaction. Argus tracked a peak move of +19.5% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $26M to the company's valuation, bringing the market cap to $160M at that time. Trading volume was exceptionally heavy at 11.3x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

PIPE gross proceeds: $35 million Shares issued: 18.9 million shares Common stock price: $1.854 per share +3 more

6 metrics

PIPE gross proceeds $35 million Definitive securities purchase agreement with RA Capital Management

Shares issued 18.9 million shares Common stock and shares underlying pre-funded warrants in PIPE

Common stock price $1.854 per share Purchase price based on five prior trading days’ average close

Pre-funded warrant price $1.8539 per warrant Price per pre-funded warrant sold in lieu of common stock

Cash runway Into 2029 Runway based on anticipated net proceeds plus existing cash

EQ504 administration Oral Investigational AhR modulator targeting colon for ulcerative colitis

Market Reality Check

Price: $2.47 Vol: Volume 473,539 is 1.34x t...

normal vol

$2.47 Last Close

Volume Volume 473,539 is 1.34x the 20-day average of 354,374 shares. normal

Technical Trading above 200-day MA with price $2.07 vs 200-day MA $1.14.

Peers on Argus

EQ was up 4.02% pre-news while close biotechnology peers like BMEA, CRBP, and FA...

1 Down

EQ was up 4.02% pre-news while close biotechnology peers like BMEA, CRBP, and FATE were down between 3–5%, indicating a stock-specific setup rather than a sector-wide move.

Historical Context

5 past events · Latest: Feb 25 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	Conference participation	Neutral	-4.7%	Announcement of participation in Leerink Partners 2026 Global Healthcare Conference.
Feb 2	Inducement grants	Neutral	+0.0%	Inducement stock option grants to new employees under 2024 Inducement Plan.
Nov 20	Conference participation	Neutral	-5.0%	Planned participation in two early December 2025 investor healthcare conferences.
Nov 13	Earnings & update	Positive	+23.8%	Q3 2025 results plus private placement and EQ504 clinical development plans.
Nov 4	Conference participation	Neutral	-7.1%	Participation in Stifel and Jefferies healthcare investor conferences with webcasts.

Pattern Detected

Earnings/operational updates with funding news have drawn positive reactions, while conference-related announcements have often coincided with share price declines.

Recent Company History

Over the past several months, Equillium combined financing and pipeline updates with corporate events. The Nov 13, 2025 Q3 results highlighted a private placement of up to $50.0M and EQ504 development, prompting a 23.81% gain. In contrast, multiple conference participation notices in Nov 2025 and Feb 2026 aligned with mid-single-digit declines. Today’s PIPE financing to advance EQ504 and extend runway into 2029 fits the pattern of capital raises linked to clinical progression.

Regulatory & Risk Context

Active S-3 Shelf · $250,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-13

$250,000,000 registered capacity

Equillium has an effective Form S-3 shelf filed on Nov 13, 2025 to offer up to $250,000,000 in various securities, including an at-the-market program of up to $75,000,000 of common stock through LifeSci Capital, which may be used for general corporate and R&D funding needs.

Market Pulse Summary

The stock surged +19.3% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +19.3% in the session following this news. A strong positive reaction aligns with the company’s pattern of responding favorably to capital and pipeline updates, as seen after the Nov 13, 2025 financing and EQ504 update. The $35 million PIPE with RA Capital extends the cash runway into 2029, but investors must weigh this against dilution capacity under the existing $250,000,000 Form S-3 and potential future usage of the $75,000,000 ATM facility.

Key Terms

pre-funded warrants, PIPE, registration statement, Form S-3, +2 more

6 terms

pre-funded warrants financial

"including shares of common stock underlying pre-funded warrants), representing a purchase"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

PIPE financial

"Equillium intends to use the net proceeds from the PIPE to further advance"

A "pipe" is a planned series of financial transactions or projects that companies intend to carry out over time, often involving the raising of funds or development of new assets. It matters to investors because it provides a clear picture of a company's future growth plans and potential revenue, helping them assess the company's upcoming opportunities and overall stability. Think of it as a detailed roadmap guiding a company's future steps.

registration statement regulatory

"except pursuant to an effective registration statement or an applicable exemption"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

Form S-3 regulatory

"resale Form S-3 registration rights for the shares of common stock issued"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

ulcerative colitis medical

"represents a next-generation therapeutic to treat Ulcerative Colitis (UC) locally."

A long-term inflammatory disease that causes repeated sores and irritation in the large intestine, leading to symptoms such as abdominal pain, urgent diarrhea, and fatigue. For investors, it matters because the condition creates a steady need for effective treatments, influences the size of drug and medical-device markets, and makes clinical trial results, regulatory decisions and treatment approvals material to companies’ revenue prospects—like watching for fixes to a recurring leak in an important building system.

aryl hydrocarbon receptor medical

"an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator"

Aryl hydrocarbon receptor (AHR) is a protein inside cells that detects certain environmental chemicals and helps turn genes on or off in response, like a smoke alarm that triggers specific reactions. It matters to investors because AHR influences how the body handles toxins and can be a target or safety concern in drug development, environmental liability assessment, and biomarker-driven regulatory decisions that affect company value.

AI-generated analysis. Not financial advice.

Capital strengthens the advancement of EQ504 through key clinical milestones

Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029

LA JOLLA, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (“Equillium” or the “Company”) (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a definitive securities purchase agreement with RA Capital Management that will provide approximately $35 million in gross proceeds to Equillium.

Pursuant to the terms of the securities purchase agreement, the Company will issue approximately 18.9 million shares of its common stock (including shares of common stock underlying pre-funded warrants), representing a purchase price of $1.854 for each share of common stock (which represents the average closing price of the Company’s common stock for the five trading days immediately prior to the financing) or $1.8539 for each pre-funded warrant sold in lieu of common stock at closing. Gross proceeds from the financing are expected to be $35 million, before deducting expenses.

Equillium intends to use the net proceeds from the PIPE to further advance clinical development of EQ504, working capital, and general corporate purposes.

“This financing strengthens our balance sheet and supports continued progress of EQ504 through its clinical development plan and is expected to fund company operations into 2029,” said Bruce Steel, Chief Executive Officer of Equillium. “RA Capital Management’s investment underscores confidence in our strategy and enables us to remain focused on disciplined execution of our upcoming EQ504 clinical objectives.”

EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator that we are developing to be administered orally. We have developed EQ504 to target the colon and believe that it represents a next-generation therapeutic to treat Ulcerative Colitis (UC) locally. We believe EQ504 has broad therapeutic potential in UC as a potential standalone oral therapy or in combination with other therapeutic approaches.

LifeSci Capital is acting as Equillium’s financial advisor.

The offer and sale of the foregoing securities to be issued in the PIPE financing are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any applicable state securities laws.  Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such state securities laws. RA Capital Management has been granted customary resale Form S-3 registration rights for the shares of common stock issued to (or that are exercisable by) them in connection with the financing.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Equillium

Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other inflammation and immunology agents. EQ504 is an investigational therapeutic program with potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.

For more information, visit www.equilliumbio.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future”, “potential” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters.

These statements include, but are not limited to, statements regarding the completion of the proposed private placement; Equillium’s intent to develop EQ504 as an orally delivered, colon-targeted treatment; Equillium’s belief that EQ504 is a next generation therapeutic; the broad therapeutic potential of EQ504 to treat ulcerative colitis, including as a mono and/or combination therapy; Equillium’s expectation that the net proceeds from the initial closing will extend its cash runway into 2029; Equillium’s expected use of the net proceeds from the private placement; and other statements that are not historical facts. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: risks and uncertainties related to market conditions; volatility in the trading price of Equillium’s common stock; Equillium’s ability to initiate or progress clinical trials on the anticipated timelines, if at all; the potential for results from clinical trials to differ from nonclinical, early clinical, preliminary or expected results; reliance on the clinical results from third-party product candidates and/or approved drugs to support advancement and the potential of Equillium’s product candidates; implementation of Equillium’s strategic plans for its business and product candidates; the sufficiency of Equillium’s capital resources and need for additional capital to achieve its goals; and other risks and uncertainties described more fully under the heading “Risk Factors” in Equillium’s Quarterly Report on form 10-Q for the quarter ended September 30, 2025 filed with the Securities and Exchange Commission (SEC), and elsewhere in Equillium’s filings and reports, which may be accessed for free by visiting the SEC’s website and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Corporate Contact 
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com

FAQ

How much did Equillium (EQ) raise from the RA Capital financing on March 13, 2026?

Equillium raised approximately $35 million in gross proceeds from the PIPE financing. According to the company, the financing comprises about 18.9 million shares (including pre-funded warrants) at roughly $1.854 per share.

What will Equillium (EQ) use the $35 million financing for and how long will it fund operations?

Equillium will use net proceeds to advance EQ504 clinical development, working capital, and general corporate purposes. According to the company, the proceeds, plus existing cash, are expected to extend the cash runway into 2029.

What are the share terms in Equillium’s PIPE with RA Capital for EQ stock?

The PIPE issues roughly 18.9 million shares, including pre-funded warrants, priced at approximately $1.854 per share. According to the company, some investors purchased pre-funded warrants in lieu of common shares at a similar per-unit price.

Does RA Capital have resale rights for Equillium (EQ) shares from the March 2026 financing?

Yes. According to the company, RA Capital was granted customary Form S-3 resale registration rights for the shares issued or exercisable by them in connection with the financing, enabling future registered resales.

How might the March 13, 2026 PIPE affect existing Equillium (EQ) shareholders?

Existing shareholders will face dilution from the issuance of approximately 18.9 million new shares and pre-funded warrants. According to the company, this capital raises liquidity but increases potential share supply and dilution risk.

What is EQ504 and why is the financing important for its development?

EQ504 is an oral aryl hydrocarbon receptor modulator targeting the colon for ulcerative colitis treatment. According to the company, the financing strengthens the balance sheet to advance EQ504 through planned clinical milestones.